The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies: Results of phase I-II trial.
 
Veronika Bachanova
Consulting or Advisory Role - Kite, a Gilead company; Seagen
Research Funding - Gamida Cell; Novartis (Inst); Unum Therapeutics (Inst)
Travel, Accommodations, Expenses - Amgen
 
Qing Cao
No Relationships to Disclose
 
Daniel Jordan Weisdorf
Consulting or Advisory Role - AbGenomics International; CSL Behring; Incyte; Pharmacyclics; Seagen
Research Funding - Alexion Pharmaceuticals; Incyte
 
Julie M Curtsinger
No Relationships to Disclose
 
Sarah A. Cooley
Research Funding - Fate Therapeutics
Travel, Accommodations, Expenses - Fate Therapeutics
 
Jeffrey Miller
Stock and Other Ownership Interests - CytoSen; Fate Therapeutics
Consulting or Advisory Role - CytoSen; Dr. Reddy's Laboratories; Fate Therapeutics; GT Biopharma; Onkimmune
Research Funding - Fate Therapeutics; GT Biopharma
Patents, Royalties, Other Intellectual Property - License IP Fate Therapeutics; License IP to GT Biopharma
Travel, Accommodations, Expenses - Dr. Reddy's Laboratories; Fate Therapeutics; GT Biopharma; Onkimmune
 
Daniel Vallera
Consulting or Advisory Role - GT Biopharma
Research Funding - GT Biopharma